Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.
Advertisement
Set Alert for Articles By Francesca Bruce

Latest From Francesca Bruce

Collaboration And Pay For Performance Deals – The Way To Pay for One-Off Treatments

New payment models, registries and the Cross Border Healthcare Directive could help determine new ways to pay for potentially one-off treatments such as gene therapies in Europe.

Europe Government Payers

Mixed HTA Results As Scotland Says No To Yescarta But Yes To Kymriah

The Scottish Medicines Consortium has recommended one CAR-T therapy, Novartis’ Kymriah, for use on Scotland’s National Health Service but rejected another, Gilead’s Yescarta, claiming the company has failed to prove it would be cost-effective.

Europe United Kingdom

England And Canada Collaborate On Parallel Scientific Advice For HTA

Health technology appraisal institutes in England and Canada are joining forces to offer parallel scientific advice and both agencies say they are open to more international collaborations.

Europe United Kingdom

International HTA Agencies Collaborate On How To Determine Value-Based Prices

Health technology assessment agencies in the US, the UK and Canada are working together to develop new ways of determining value-based prices for potentially curative treatments like gene therapies.

Europe United Kingdom

UK Has Sought Advice On Compulsory Licensing For Vertex’ Orkambi

Pressure on Vertex over access to its cystic fibrosis drug Orkambi in England is mounting after the parliamentary undersecretary for health admitted the government has already taken advice on compulsory licensing of the product.

Europe United Kingdom

UK: Funding For Second Kymriah Indication After Talks And Price Cut

UK HTA body NICE says a second indication for Novartis’s groundbreaking CAR-T cell therapy Kymriah should be covered under the Cancer Drugs Fund.

Europe United Kingdom
See All
Advertisement
UsernamePublicRestriction

Register